These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8735202)

  • 41. Diagnostic performance of Triage for benzodiazepines: urine analysis of the dose of therapeutic cases.
    Kurisaki E; Hayashida M; Nihira M; Ohno Y; Mashiko H; Okano T; Niwa S; Hiraiwa K
    J Anal Toxicol; 2005 Sep; 29(6):539-43. PubMed ID: 16168176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of cross-reactivity of Ambien (zolpidem) with drugs in standard urine drug screens.
    Piergies AA; Sainati S; Roth-Schechter B
    Arch Pathol Lab Med; 1997 Apr; 121(4):392-4. PubMed ID: 9140309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
    Fraser AD; Howell P
    J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance of AdultaCheck 4 test strips for the detection of adulteration at the point of collection of urine specimens used for drugs-of-abuse testing.
    King EJ
    J Anal Toxicol; 1999; 23(1):72. PubMed ID: 10022215
    [No Abstract]   [Full Text] [Related]  

  • 45. Improved screening for benzodiazepine metabolites in urine using the Triage Panel for Drugs of Abuse.
    Koch TR; Raglin RL; Kirk S; Bruni JF
    J Anal Toxicol; 1994; 18(3):168-72. PubMed ID: 7914948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urine drug screening results from volunteers in phase I clinical pharmacology studies: are we being misled?
    Ramey KL; Kovacs SJ; Martin DE; Jorkasky DK
    J Clin Pharmacol; 1998 May; 38(5):413-6. PubMed ID: 9602952
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum gentamicin levels: a comparison between the Syva Solaris and the Syva QST analysers.
    Bearman J; Ellis J; Mortlock S
    Br J Biomed Sci; 1995 Jun; 52(2):102-5. PubMed ID: 8520246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CEDIA for screening drugs of abuse in urine and the effect of adulterants.
    Wu AH; Forte E; Casella G; Sun K; Hemphill G; Foery R; Schanzenbach H
    J Forensic Sci; 1995 Jul; 40(4):614-8. PubMed ID: 7595298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison between GC-MS and the EMIT II, Abbott ADx, and Roche OnLine immunoassays for the determination of THCCOOH.
    Kintz P; Machart D; Jamey C; Mangin P
    J Anal Toxicol; 1995 Sep; 19(5):304-6. PubMed ID: 7500617
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost effective EMIT assays, for drugs of abuse in urine, using the Eppendorf EPOS analyser.
    Gooch JC; Caldwell R; Turner GJ; Colbert DL
    J Immunoassay; 1992; 13(1):85-96. PubMed ID: 1569214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated urine zinc concentration reduces the detection of methamphetamine, cocaine, THC and opiates in urine by EMIT.
    Lin CN; Strathmann FG
    J Anal Toxicol; 2013; 37(9):665-9. PubMed ID: 23843421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary screening for benzodiazepines with radioreceptor assay: comparison with EMIT d.a.u. benzodiazepine assay and high-performance liquid chromatography.
    Borggaard B; Joergensen I
    J Anal Toxicol; 1994 Sep; 18(5):243-6. PubMed ID: 7990439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens.
    Arntson A; Ofsa B; Lancaster D; Simon JR; McMullin M; Logan B
    J Anal Toxicol; 2013 Jun; 37(5):284-90. PubMed ID: 23625703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. European multicentre evaluation of the analytical performance of the Abbott AxSYM Abused Drugs Assays.
    von Meyer L; Hänseler E; Lardet G; Scholer A; Sieghart W
    Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):133-40. PubMed ID: 9056758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Agreement between two measures of drug use in a low-prevalence population.
    Hancock L; Hennrikus D; Henry DA; Sanson-Fisher R; Walsh R; Lewis JH
    Addict Behav; 1991; 16(6):507-16. PubMed ID: 1801574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lower Cutoffs for LC-MS/MS Urine Drug Testing Indicates Better Patient Compliance.
    Krock K; Pesce A; Ritz D; Thomas R; Cua A; Rogers R; Lipnick P; Kilbourn K
    Pain Physician; 2017 Nov; 20(7):E1107-E1113. PubMed ID: 29149155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the Abuscreen ONLINE assay for amphetamines on the Hitachi 737: comparison with EMIT and GC/MS methods.
    Baker DP; Murphy MS; Shepp PF; Royo VR; Caldarone ME; Escoto B; Salamone SJ
    J Forensic Sci; 1995 Jan; 40(1):108-12. PubMed ID: 7876791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of low serum methotrexate concentrations with the Syva Emit Methotrexate Assay.
    Demedts P; Vanden Wyngaerd A; Wauters A; Neels H
    Ther Drug Monit; 1997 Oct; 19(5):545-6. PubMed ID: 9357100
    [No Abstract]   [Full Text] [Related]  

  • 59. Reducing false-negative tests in urinary drugs-of-abuse screening.
    Luceri F; Godi F; Messeri G
    J Anal Toxicol; 1997; 21(3):244-5. PubMed ID: 9171214
    [No Abstract]   [Full Text] [Related]  

  • 60. Urine adulteration with denture-cleaning tablets.
    Stolk LM; Scheijen JL
    J Anal Toxicol; 1997 Sep; 21(5):403. PubMed ID: 9288596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.